• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

代谢物形成的药代动力学:通过反卷积确定代谢物形成的速率和程度。

Metabolite formation pharmacokinetics: rate and extent of metabolite formation determined by deconvolution.

作者信息

Karol M D, Goodrich S

机构信息

Department of Pharmaceutical Sciences, College of Pharmacy, University of Arizona, Tucson 85721.

出版信息

Pharm Res. 1988 Jun;5(6):347-51. doi: 10.1023/a:1015951426191.

DOI:10.1023/a:1015951426191
PMID:2469080
Abstract

A two-step analytic procedure to determine the rate and extent of metabolite production following administration of the parent compound is described. The procedure provides the rate and extent of metabolite production as a function of time by application of the general model independent approach of deconvolution. The metabolite unit impulse response function is obtained by implicit deconvolution of the metabolite data with a truncated constant-rate metabolite input function. Then the obtained unit impulse response function is used in an analytic deconvolution with metabolite data following administration of the parent compound to obtain the rate and extent of metabolite production. The input function is also deconvolved with metabolite data to obtain the unit impulse response function appropriate for prediction of metabolite levels given a selected input of parent compound. The expected profile following administration of the consecutive infusions of parent drug is shown for both parent and metabolite. The rationale for selection of deconvolution methods is discussed. The approach is applied to data for procainamide and N-acetylprocainamide from three human subjects. The results indicate that from 27 to 39% of the procainamide was converted to N-acetylprocainamide in these subjects.

摘要

本文描述了一种两步分析程序,用于确定母体化合物给药后代谢产物生成的速率和程度。该程序通过应用反卷积的通用模型无关方法,将代谢产物生成的速率和程度表示为时间的函数。代谢产物单位脉冲响应函数通过将代谢产物数据与截断的恒定速率代谢产物输入函数进行隐式反卷积获得。然后,将获得的单位脉冲响应函数用于与母体化合物给药后的代谢产物数据进行解析反卷积,以获得代谢产物生成的速率和程度。输入函数也与代谢产物数据进行反卷积,以获得在选定母体化合物输入情况下适合预测代谢产物水平的单位脉冲响应函数。展示了连续输注母体药物后母体和代谢产物的预期曲线。讨论了选择反卷积方法的基本原理。该方法应用于来自三名人类受试者的普鲁卡因胺和N-乙酰普鲁卡因胺的数据。结果表明,在这些受试者中,27%至39%的普鲁卡因胺转化为N-乙酰普鲁卡因胺。

相似文献

1
Metabolite formation pharmacokinetics: rate and extent of metabolite formation determined by deconvolution.代谢物形成的药代动力学:通过反卷积确定代谢物形成的速率和程度。
Pharm Res. 1988 Jun;5(6):347-51. doi: 10.1023/a:1015951426191.
2
Pharmacokinetics of procainamide and N-acetylprocainamide in rats.普鲁卡因胺和N-乙酰普鲁卡因胺在大鼠体内的药代动力学
J Pharm Sci. 1981 Mar;70(3):299-302. doi: 10.1002/jps.2600700319.
3
Antiarrhythmic efficacy, pharmacokinetics and safety of N-acetylprocainamide in human subjects: comparison with procainamide.N-乙酰普鲁卡因胺在人体中的抗心律失常疗效、药代动力学及安全性:与普鲁卡因胺的比较
Am J Cardiol. 1980 Sep;46(3):463-8. doi: 10.1016/0002-9149(80)90016-8.
4
The influence of selected general anesthetics on pharmacokinetic parameters of some antiarrhythmic drugs in rabbits. Part I. Procainamide and its active metabolite-N-acetylprocainamide.
Acta Pol Pharm. 1995 Mar-Apr;52(2):141-6.
5
A simple integrated method for drug and derived metabolite kinetics. An application of the statistical moment theory.一种用于药物及其代谢产物动力学的简单综合方法。统计矩理论的应用。
Drug Metab Dispos. 1982 Sep-Oct;10(5):474-9.
6
Metabolism of procainamide in the perfused rat liver.普鲁卡因酰胺在灌注大鼠肝脏中的代谢。
Drug Metab Dispos. 1981 May-Jun;9(3):183-7.
7
Clinical pharmacokinetics of N-acetylprocainamide.N-乙酰普鲁卡因胺的临床药代动力学
Clin Pharmacokinet. 1982 May-Jun;7(3):206-20. doi: 10.2165/00003088-198207030-00002.
8
The influence of moderate and chronic exercise training on the pharmacokinetics of procainamide and N-acetylprocainamide.适度和长期运动训练对普鲁卡因胺及N - 乙酰普鲁卡因胺药代动力学的影响。
Biopharm Drug Dispos. 1998 Jul;19(5):291-6. doi: 10.1002/(sici)1099-081x(199807)19:5<291::aid-bdd106>3.0.co;2-x.
9
[Clinical pharmacology of procainamide and its active metabolite -N-acetylprocainamide].
Przegl Lek. 1984;41(5):379-83.
10
[Simultaneous predictions of disposition kinetics of procainamide and its metabolite N-acetylprocainamide in rat by a physiological pharmacokinetic model].[通过生理药代动力学模型同时预测大鼠体内普鲁卡因胺及其代谢物N-乙酰普鲁卡因胺的处置动力学]
Yao Xue Xue Bao. 1991;26(10):725-32.

引用本文的文献

1
Pharmacokinetics and bioinversion of ibuprofen enantiomers in humans.布洛芬对映体在人体内的药代动力学和生物转化
Pharm Res. 1994 Jun;11(6):824-30. doi: 10.1023/a:1018969506143.
2
The pharmacokinetics of trilostane and ketotrilostane in an interconverting system in the rat.
Pharm Res. 1992 Apr;9(4):464-8. doi: 10.1023/a:1015828027060.

本文引用的文献

1
An algorithm and computer program for deconvolution in linear pharmacokinetics.一种用于线性药代动力学中去卷积的算法及计算机程序。
J Pharmacokinet Biopharm. 1980 Oct;8(5):463-81. doi: 10.1007/BF01059546.
2
Pharmacokinetic analysis by linear system approach I: cimetidine bioavailability and second peak phenomenon.
J Pharm Sci. 1981 Jan;70(1):32-8. doi: 10.1002/jps.2600700105.
3
Comparison of antiarrhythmic effects of procainamide, N-acetylprocainamide, and p-hydroxy-N-(3-diethylaminopropyl)benzamide.普鲁卡因胺、N-乙酰普鲁卡因胺和对羟基-N-(3-二乙氨基丙基)苯甲酰胺抗心律失常作用的比较。
Proc Soc Exp Biol Med. 1982 Feb;169(2):156-60. doi: 10.3181/00379727-169-41325.
4
A commentary: methods and assumptions in the kinetic estimation of metabolite formation.一篇评论:代谢物生成动力学估算中的方法与假设
Drug Metab Dispos. 1983 Mar-Apr;11(2):79-84.
5
A review of metabolite kinetics.代谢物动力学综述。
J Pharmacokinet Biopharm. 1985 Dec;13(6):633-62. doi: 10.1007/BF01058905.
6
Gastrointestinal bioavailability: determination of in vivo release profiles of solid oral dosage forms by deconvolution.胃肠道生物利用度:通过反卷积法测定固体口服剂型的体内释放曲线
Biopharm Drug Dispos. 1985 Jul-Sep;6(3):351-5. doi: 10.1002/bdd.2510060311.
7
Correlation of the electrophysiological and antiarrhythmic properties of the N-acetyl metabolite of procainamide with plasma and tissue drug concentrations in the dog.普鲁卡因酰胺N-乙酰代谢物的电生理和抗心律失常特性与犬血浆及组织药物浓度的相关性
J Pharmacol Exp Ther. 1976 Apr;197(1):38-48.
8
Do you need a pharmacokinetic model, and, if so, which one?你需要一个药代动力学模型吗?如果需要,是哪一种呢?
J Pharmacokinet Biopharm. 1975 Dec;3(6):457-78. doi: 10.1007/BF01059477.
9
Curve fitting and modeling in pharmacokinetics and some practical experiences with NONLIN and a new program FUNFIT.药代动力学中的曲线拟合与建模以及使用NONLIN和新程序FUNFIT的一些实践经验。
J Pharmacokinet Biopharm. 1977 Oct;5(5):513-31. doi: 10.1007/BF01061732.
10
Procainamide and N-acetylprocainamide kinetics investigated simultaneously with stable isotope methodology.采用稳定同位素方法同时研究普鲁卡因胺和N-乙酰普鲁卡因胺的动力学。
Clin Pharmacol Ther. 1977 Oct;22(4):447-57. doi: 10.1002/cpt1977224447.